Osteoarthritis, Knee
Conditions
Brief summary
Evaluation of the performance and safety of ArToFILL in subjects with mild to moderate osteoarticular pain
Detailed description
Monocenter, prospective, open label, interventional clinical investigation evaluating the performance and safety of 3 intra-articular injections of ArToFILL for the treatment of mild-moderate osteoarticular pain.
Interventions
DEVICEArToFILL
ArToFILL is an injectable medical device (class III) intended for use as a temporary filler in joints. It is a sterile, non-pyrogenic, colorless and transparent hyaluronic acid gel of non-animal origin. ArToFILL is a hydrogel consisting of a mixture of two different molecular weights of hyaluronic acid, for a total HA concentration of 2.7 %.
Sponsors
PromoPharma spa
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
* Patient (males and females) aged between 18 and 84 years (limits included); * Patient able to understand the nature and purpose of the study, including possible risks and side effects; * Patient able to provide written Informed Consent, in accordance with good clinical practice and current legislation; * Pain ≥ 40 mm on the VAS score in the target knee for at least 2 months; * Patient with knee osteoarthritis assessed radiographically, grade 1 to 3 according to the Kellgren-Lawrence scale (K-L); * Body Mass Index (BMI) ≤ 35; * Patient who will benefit from this treatment; * Patient available for the entire study period; * Patient able to cooperate and meet the requirements of the clinical investigation plan.
Exclusion criteria
* Patient with knee osteoarthritis, assessed radiographically, grade 4 by the K-L scale; * Patient presenting ongoing inflammation/infection at the level of the joint being investigated; * Patient with abundant intra-articular effusion; * Patient with symptoms of viral or bacterial infections or similar; * Patient with insertion point of the joint infected or in the presence of a skin disease; * Simultaneous treatment with disinfectants containing quaternary ammonium salts or chlorhexidine; * Patient with known or potential allergy or hypersensitivity and/or history of allergic reactions to one of the components of the medical device; * Concomitant treatments with thrombolytic or anticoagulant therapies, for less than 2 weeks prior to the screening visit; * Intra-articular treatments carried out in the last 3 months (9 months if with products containing hyaluronic acid) of the target joint; * Topical treatments of the target joint in progress or performed within 1 week of the screening visit; * Taking NSAIDs and/or paracetamol as rescue treatment for more than two consecutive days; * Surgical interventions of prosthetic replacement in the target joint; * Physiotherapy and instrumental physical therapy treatments for the target joint performed in the last 2 weeks prior to the screening visit, and during the study period; * Participation in another clinical trial within 60 days prior to the screening visit; * Evidence of severe or uncontrolled systemic disease or any other significant disorder (e.g. haemophilia, bleeding disorders etc.); which do not allow participation in the study or could compromise the results. * Patients who are pregnant or breastfeeding; * Subject unable to follow clinical investigation procedures and follow-up visits; * Any other medical condition which could influence participation in the clinical investigation or compromise its results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction ≥ of 15 points on VAS scale, at the Study Termination Visit compared to baseline | Up to 180 days | Assessment of pain reduction using the visual analogue scale (VAS) ranging from 0 to 100 mm (where 0 = absent and 100 = strongest pain) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Up to 180 days | Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. The total score is the result of the sum of 3 groups of questions with 5 possible answers (between 0 and 4, where 0=none and 4=extreme) for the self-assessment of: * pain:five questions (score from 0 to 20); * joint stiffness: two questions (score from 0 to 8); * functional limitations: 17 questions (score from 0 to 68). |
| Improved range of motion (ROM) of the knee joint | Up to 180 days | The variation of the ROM joint excursion used for the analysis of the joint excursion (flexion-extension), will be calculated as the difference between maximum width and minimum width of the angular profile on the basis of the following formula: ROMα = max (α) - min (α) (flexion-extension) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of the safety and tolerability of treatment of medical device. | 180 days | Investigator Global Assessment of Safety (IGAS): using the 4- point scale:1= very good safety, 2 =good safety, 3 = moderate safety and 4 = poor safety. Counting the number of files used for the patient confirmed by the number of traceability labels detached and kept by the Investigator |
Countries
Italy
Contacts
Primary ContactMichele Vecchio
Outcome results
None listed